ZA904915B - Varicella-zoster virus glycoproteins gpi,gpii and gpiii and their use in vaccines - Google Patents

Varicella-zoster virus glycoproteins gpi,gpii and gpiii and their use in vaccines

Info

Publication number
ZA904915B
ZA904915B ZA904915A ZA904915A ZA904915B ZA 904915 B ZA904915 B ZA 904915B ZA 904915 A ZA904915 A ZA 904915A ZA 904915 A ZA904915 A ZA 904915A ZA 904915 B ZA904915 B ZA 904915B
Authority
ZA
South Africa
Prior art keywords
gpiii
gpii
varicella
vaccines
zoster virus
Prior art date
Application number
ZA904915A
Other languages
English (en)
Inventor
Alex Bollen
Bollen Alex
Michel Heinderyckx
Heinderyckx Michel
Marc Massaer
Massaer Marc
Diane Gregoire
Gregoire Diane
Paul Jacobs
Jacobs Paul
Original Assignee
Smithkline Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Biolog filed Critical Smithkline Biolog
Publication of ZA904915B publication Critical patent/ZA904915B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrically Driven Valve-Operating Means (AREA)
  • Piezo-Electric Or Mechanical Vibrators, Or Delay Or Filter Circuits (AREA)
  • Liquid Crystal (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA904915A 1989-06-27 1990-06-25 Varicella-zoster virus glycoproteins gpi,gpii and gpiii and their use in vaccines ZA904915B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37177289A 1989-06-27 1989-06-27

Publications (1)

Publication Number Publication Date
ZA904915B true ZA904915B (en) 1991-06-26

Family

ID=23465352

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA904915A ZA904915B (en) 1989-06-27 1990-06-25 Varicella-zoster virus glycoproteins gpi,gpii and gpiii and their use in vaccines

Country Status (14)

Country Link
EP (1) EP0405867B1 (fr)
JP (1) JPH0349694A (fr)
KR (1) KR0166585B1 (fr)
AT (1) ATE119939T1 (fr)
AU (1) AU625328B2 (fr)
CA (1) CA2019845A1 (fr)
CY (1) CY1933A (fr)
DE (1) DE69017769T2 (fr)
DK (1) DK0405867T3 (fr)
ES (1) ES2071770T3 (fr)
IE (1) IE66516B1 (fr)
NZ (1) NZ234222A (fr)
PT (1) PT94479B (fr)
ZA (1) ZA904915B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824319A (en) * 1990-10-04 1998-10-20 Research Corporation Technologies, Inc. Varicella-zoster virus antigen
ES2150906T3 (es) * 1990-10-04 2000-12-16 Res Corp Technologies Inc Antigeno del virus varicella-zoster.
WO1994002596A1 (fr) * 1992-07-17 1994-02-03 Merck & Co., Inc. Methode de prevention d'herpes-zoster ou de soulagement de nevralgie post-herpetique associee a la varicelle
GB9226768D0 (en) * 1992-12-23 1993-02-17 Smithkline Beecham Biolog Vaccines
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
US5834441A (en) * 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
KR970006484A (ko) * 1995-07-27 1997-02-21 수두 바이러스의 당단백질을 대량발현시키는 동물세포주
KR100365986B1 (ko) * 1996-02-09 2003-02-20 스미스클라인 비이참 바이오로지칼즈 에스.에이. 수두대상포진바이러스유전자63생성물에대한백신
US7112331B2 (en) 1996-02-09 2006-09-26 Smithkline Beecham Biologicals, S.A. Vaccines against varicella zoster virus gene 63 product
KR100434023B1 (ko) * 1996-02-29 2005-05-09 주식회사 엘지생명과학 수두바이러스의당단백질을대량발현시키는동물세포주
DE19757767A1 (de) 1997-12-23 1999-07-15 Dade Behring Marburg Gmbh Immunreaktive Bereiche des Glycoproteins gpII des Varicella-Zoster-Virus (VZV)
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2014043189A1 (fr) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Virus de l'herpès déficients pour la réplication conditionnelle et leur utilisation dans des vaccins
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CN110621339A (zh) 2017-04-28 2019-12-27 葛兰素史密丝克莱恩生物有限公司 疫苗接种
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
EP3833382A1 (fr) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processus et vaccins
EP3886901A1 (fr) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Procédés de fabrication d'un adjuvant
WO2020245207A1 (fr) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Purification de saponine
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
CN112142829B (zh) * 2019-06-28 2022-02-22 怡道生物科技(苏州)有限公司 水痘-带状疱疹病毒gE蛋白突变体及其表达方法
BR112022017852A2 (pt) 2020-03-09 2022-11-01 Dynavax Tech Corp Vacinas para herpes zoster compreendendo um agonista de tlr9
CN115819616B (zh) * 2021-07-28 2025-04-11 江苏瑞科生物技术股份有限公司 一种基因重组vzv融合蛋白及其制备方法和应用
EP4169513A1 (fr) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Composition d'adjuvant comprenant des agonistes du sting
EP4558170A1 (fr) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Procédé continu de production de vaccin
WO2025052001A1 (fr) 2023-09-07 2025-03-13 Mnemo Therapeutics Procédés et compositions pour améliorer la réponse immunitaire

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE118353T1 (de) * 1984-04-06 1995-03-15 Chiron Corp Rekombinanter herpes simplex gb-gd impfstoff.
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
US4769239A (en) * 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
EP0211756A1 (fr) * 1985-08-01 1987-02-25 Merck & Co. Inc. Essai pour anticorps de virus Varicella-Zoster (VZV)
US4686101A (en) * 1985-08-02 1987-08-11 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4952674A (en) * 1986-05-02 1990-08-28 Merck & Co., Inc. Vaccine against varicella-zoster virus
JPH02504103A (ja) * 1987-06-30 1990-11-29 ジ・アップジョン・カンパニー 減少したｏ‐連結グリコシレーションを有するウイルスタンパク質

Also Published As

Publication number Publication date
PT94479A (pt) 1991-02-08
EP0405867A1 (fr) 1991-01-02
EP0405867B1 (fr) 1995-03-15
HK1006468A1 (en) 1999-02-26
PT94479B (pt) 1997-05-28
IE902297L (en) 1990-12-27
ATE119939T1 (de) 1995-04-15
CY1933A (en) 1990-06-22
DE69017769T2 (de) 1995-07-13
IE902297A1 (en) 1991-01-16
CA2019845A1 (fr) 1990-12-27
AU625328B2 (en) 1992-07-09
JPH0349694A (ja) 1991-03-04
AU5779290A (en) 1991-01-03
ES2071770T3 (es) 1995-07-01
DK0405867T3 (da) 1995-05-22
DE69017769D1 (de) 1995-04-20
NZ234222A (en) 1992-03-26
KR910001060A (ko) 1991-01-30
IE66516B1 (en) 1996-01-10
KR0166585B1 (ko) 1999-01-15

Similar Documents

Publication Publication Date Title
ZA904915B (en) Varicella-zoster virus glycoproteins gpi,gpii and gpiii and their use in vaccines
GB2246784B (en) Herpes virus recombinant poxvirus vaccine
IL96647A0 (en) Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
GB2264949B (en) Measles virus recombinant poxvirus vaccine
GB8921470D0 (en) Vaccines
DE69016245D1 (de) Artikel zur Gewebekonditionierung.
FI915702A7 (fi) Peptidejä ja niistä johdettuja vasta-aineita HTLV-1 infektion vastaise n rokotuksen määrittämiseksi
EP0453497A4 (en) Treatment methods and vaccines
HU901571D0 (en) Vaccine and diagnostics against the virus of pig-cholera
ZA906543B (en) Pseudorabies virus not occurring in nature and vaccines containing the same
ZA905296B (en) Use of bluetongue virus proteins as vaccines components
ZA908189B (en) Infectious bronchitis virus vaccine
DE69428610D1 (de) Methoden zur kultivierung von infektiösem laryngotracheitis virus und von "egg-drop-syndrome" verursachendem virus
NZ224862A (en) Taenia ovis antigens and vaccines
HU9203976D0 (en) Vaccine based on modified herpes virus
ZA905813B (en) Avipox virus promoters
ZA919198B (en) Measles virus recombinant poxvirus vaccine
AU6051396A (en) Measles virus recombinant poxvirus vaccine
AU5953190A (en) Vaccine against bovine leukemia virus
ZA902894B (en) Herpesvirus recombinant poxvirus vaccine
EP0043847A4 (fr) Vaccin de virus de varicelle fortement attenue et production de celui-ci.
ZA903475B (en) Novel proteins and the preparation thereof
GB8919356D0 (en) Vaccine against varicella zoster virus and method for its preparation
IE892784L (en) Vaccines
GB8926832D0 (en) Vaccines